SciELO - Scientific Electronic Library Online

 
vol.20 número2Control de un brote epidémico de enfermedad meningocócica por N. meningitidis serogrupo BTrombofilia y pérdida recurrente de embarazo índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Links relacionados

Compartilhar


Revista Médica del Uruguay

versão On-line ISSN 1688-0390

Resumo

GOYETCHE, Rosario et al. Efectos adversos asociados a la vacuna antimeningocócica VA-MENGOCC-BCR. Rev. Méd. Urug. [online]. 2004, vol.20, n.2, pp.102-105. ISSN 1688-0390.

Summary Background. The first massive vaccination campaign with VA-MENGOCC-BCR antimeningococcal vaccine in Uruguay was set up in December 2001. In Santa Lucía city (Canelones) 5 366 children and youths were vaccinated. The vaccine is thought to be harmless, main adverse reactions recorded are local. Objective. To determine the prevalence and types of adverse reactions associated to VA-MNGOCC-BCR antimeningococcal vaccines in this population. Method. A sample of 744 children were randomly assigned to the study. Adverse reactions were recorded after the first and the second dosage by personal interview or by phone 30 days later than dosages. Results. Among the 744 children, 728 were assessed (98%). Adverse reactions were seen in 53% (IC95 53% + 3,6): 30% after the first intake, 5% after the second and 18% between the first and the second dosage. Adverse reactions were not seen in 47% (IC95 47% + 3,6). Among the 659 recorded adverse reactions, 71% were local and 29% systemic. Pain was the most frequent local adverse reaction, fatigue was the most frequent systemic adverse reaction. Conclusion. The prevalence of adverse reactions in this population was 53% (IC95 53% + 3,6). There were no severe adverse reactions. Results are coincident with other series.

Palavras-chave : VACUNA ANTIMENINGOCOCICA BC [efectos adversos].

        · resumo em Espanhol | Francês     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons